Bhatnagar Anish

Bhatnagar Anish, listed as chief executive, appears in our data through filings on Soleno Therapeutics Inc shares, published by SEC (Form 4). The record holds 20 filings, for trades running from 21 January 2022 to 21 January 2026.

Market trades split into 1 purchase and 12 sales (€8.5M). The totals do not cover 1 filing with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 6 share grants and 1 option exercise.

The latest filing, published on 23 January 2026, reports a share grant in Soleno Therapeutics Inc. The clock since the last published purchase (4 April 2022) now reads 1,658 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.